NRx Pharma's COVID-19 Vaccine Displays Effectiveness Against Delta Variant in Phase 2 Clinical Trial
Source: Streetwise Reports
November 30, 2021 (Investorideas.com Newswire) Shares of NRx Pharmaceuticals Inc. traded 50% higher after the company commented on new data released by the Israel Institute for Biological Research regarding the effectiveness of its BriLife® COVID-19 Vaccine against the SARS-CoV-2 "Delta" variant.
Clinical-stage pharmaceutical company NRx Pharmaceuticals Inc. (NRXP:NASDAQ), which is focused on creating and developing life-saving treatments for medical conditions and diseases with no approved therapies or cures, announced that "the Israel Institute for Biological Research (IIBR) has posted scientific results from an initial sample of phase 2 vaccinated patients in order to assess the potential effectiveness of the BriLife® vaccine against the Delta variant of the SARS-CoV-2 virus. Blood (Sera) from an initial sample of 11 trial participants demonstrated effective neutralizing antibodies against the original "wild-type" Coronavirus and was tested for antibodies to the Delta variant."
The company noted that in 10 of the 11 tested samples collected during the Phase 2 study, the BriLife® vaccine was shown to have effectively neutralized the Delta variant.
The firm indicated further that additional blood samples (sera) had been drawn from a second group of non-randomized, unvaccinated patients who had contracted and recovered from Covid-19. NRx Pharmaceuticals stated that "those patients had antibodies against the "wild-type" Coronavirus but with a 3.8-fold reduction in immune response (neutralizing titers) to the Delta variant."
The company explained that BriLife® is a live-virus vaccine and that the scientific data released by the IIBR suggests that "mutations seen in the BriLife vaccine may be responsible for effectiveness against variants occurred naturally as a function of the spontaneous acquisition of new characteristics."
NRx Pharma elaborated that according to the manuscript prepared by the IIBR, "spontaneously-acquired mutations such as N501Y and E484D, that occurred during BriLife® development and correspond to naturally-occurring mutations of SARS-CoV-2 variants, may increase the potential of BriLife® to maintain effectiveness against current SARS-CoV-2 variants, and potentially against future variants of concern."
The company indicated that this week the study's Data Safety Monitoring Board will be performing a full review of the Phase 2 results. The firm stated that after the reviews is completed it intends to proceed immediately with commencement of a Phase 2b/3 registration trial of the BriLife® vaccine.
NRx Pharmaceuticals' CEO and Chairman Prof. Jonathan Javitt commented, "These early findings from the BriLife phase 2 trial are highly encouraging at a time when new variants of concern increasingly threaten the immunity we have built with first-generation vaccines...Although these are early results from a subsample of patients treated in a phase 2 trial, all phase 2a patients are now more than 60 days post-vaccination, and we await a review by the independent Data Safety Monitoring Board in the coming week. Should the full cohort of vaccinated patients demonstrate results comparable to this reported subgroup, that would be indicative of potential vaccine effectiveness against new variants of the virus."
NRx Pharmaceuticals is a clinical-stage pharmaceutical company headquartered in Radnor, Pa. The firm is presently involved in advancing the BriLife® Covid vaccine, which it said was developed by the Israel Institute for Biological Research, under an exclusive license from the Israel Ministry of Defense.
In addition, the company is also conducting Phase 3 trials for ZYESAMI® (aviptadil) to treat respiratory failure in patients with COVID-19. The firm noted that ZYESAMI® (aviptadil) has been awarded Fast Track designation by the U.S. Food and Drug Administration (FDA) and advised that the "Phase 3 studies are being funded by the U.S. National Institutes of Health, the Biomedical Advanced Research and Development Authority (BARDA) of the U.S. Department of Health and Human Services and the Medical Countermeasures program, part of the U.S. Department of Defense."
The company has also been granted Breakthrough Therapy Designation for its NRX-101, an oral therapeutic for use in treating acute suicidal behavior/ideation in bipolar depression. The firm indicated that NRX-101 is currently being evaluated in Phase 3 trials with data readouts expected in 2022.
NRx Pharmaceuticals started off the day on Friday with a market capitalization of around $264.6 million with approximately 58.81 million shares outstanding. NRXP shares opened about 3.00% higher at $4.62 (+$0.12, +2.67%) over the prior trading day's $4.50 closing price. The stock traded Friday between $4.3979 and $8.89 per share and closed for trading at $6.75 (+$2.25, +50.00%).
1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the decision to publish an article until three business days after the publication of the article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.
This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.
More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com